Possible Facilitative Effects of Repeated Anodal Transcranial Direct Current Stimulation on Functional Outcome 1 Month Later in Schizophrenia: An Open Trial

Zui Narita1*, Takuma Inagawa1, Kazuki Sueyoshi2, Crystal Lin2 and Tomiki Sumiyoshi2

1 Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan, 2 Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo, Japan

Recent research on neuromodulation techniques, such as transcranial direct current stimulation (tDCS), for the treatment of schizophrenia has mainly focused on psychotic symptoms. We aimed to determine whether repetitive tDCS is efficacious in improving determinants of outcome, such as cognitive function, daily living skills, and depressive mood in patients with schizophrenia. Twenty-eight patients underwent tDCS (2 mA × 20 min) two times per day for 5 consecutive days. The anodal electrode was placed over the left dorsolateral prefrontal cortex while the cathodal electrode was placed over the right supraorbital region. One month after the last stimulation, there was a significant improvement on cognitive function, measured by the brief assessment of cognition in schizophrenia (d = 0.49). Significant effects were also shown on daily living skills (functional capacity), measured by the UCSD performance-based skills assessment-brief (d = 0.70). Depressive symptoms, measured by the Calgary depression rating scale, as well as psychotic symptoms measured by on the positive and negative syndrome scale positive and general psychopathology subscales also responded to the treatment (d = 0.38, d = 0.48, and d = 0.50, respectively). This is the first study to suggest that tDCS with the anodal electrode on the left prefrontal cortex improves functional capacity and depressive symptoms in patients with schizophrenia. These results may add to the concept that tDCS provides a strategy to enhance functional outcomes in patients with schizophrenia.

Trial Registration: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recpt-no=R000018556, UMIN000015953.

Keywords: brain stimulation, cognition, daily living skills, tDCS, functional outcome

INTRODUCTION

Schizophrenia patients elicit psychotic symptoms, mood symptoms, and cognitive impairment (1–3). Specifically, cognitive function, such as learning memory, working memory, executive function, verbal fluency, and attention/information processing, are impaired in patients with the illness (4, 5). Functional capacity is defined as the potential to perform everyday living activities, which require financial competence, communication skills, and so on (6). By contrast, real-world functional outcomes (social function) are greatly affected by several factors, such as opportunities and incentives...
that influence functioning in everyday situations (7). These levels of functional outcomes (cognitive function, functional capacity, social function) have been reported to be associated with each other (8, 9).

In patients with schizophrenia, functional connectivity of the frontoparietal control network and inter-hemispheric connectivity are decreased, which may play an important role in the pathophysiology of impairment of higher order cognitive task-related activities (10–12). The dorsolateral prefrontal cortex (DLPFC) is reported to be related to these circuits, and shows functional changes of cognitive function in schizophrenia (13, 14). Transcranial direct current stimulation (tDCS) is a feasible and safe method, using weak and direct electrical current to the brain through electrodes (15, 16). tDCS changes cortical excitability, modulated by glutamatergic activity via actions on catecholamine, acetylcholine and serotonin receptors (17–19). With this mechanism, tDCS over the left DLPFC has been suggested to modulate corticosubcortical/corticocortical pathways (20, 21).

The beneficial effect of tDCS on cognitive function has been reported. For example, Vercammen et al. observed that a subset of patients with schizophrenia, with greater variance in the active relative to the sham conditions, may respond to tDCS over the DLPFC (22). In addition, Schretlen et al. reported facilitative effects of tDCS over the left DLPFC on measures of working memory and aspects of verbal fluency relevant to word retrieval (18). Moreover, Hoy et al. found that repeated tDCS over the left DLPFC may enhance working memory in schizophrenia by restoring normal gamma oscillatory function (23). Furthermore, a sham-controlled randomized study demonstrated that repeated tDCS over the left DLPFC improved performance on the MATRICS Consensus Cognitive Battery (24). Thus, the DLPFC has been a target for studies investigating tDCS on cognitive function in schizophrenia (18, 22–24).

Although these studies indicate the facilitative effect of tDCS over the DLPFC on some domains of cognitive function, there is little information on whether tDCS would improve a higher level of functional outcome, e.g., daily living skill linked to cognitive function (functional capacity), in schizophrenia. We hypothesized that tDCS may also be effective in improving functional capacity in schizophrenia, since this level of functional outcome is associated with cognitive function, as mentioned above (8, 9). To our knowledge, no study has been attempted to determine whether tDCS directly improves functional capacity, or the improvement on other symptoms, such as psychosis, depression, would indirectly improve it. Based on these considerations, the primary aim of present study was to evaluate the effect of anodal tDCS over the left DLPFC on functional capacity in schizophrenia. Also, we sought to determine whether or not a putative improvement of functional capacity by tDCS would be related to changes of other clinical factors, such as cognition, psychotic symptoms, and depressive symptoms.

**MATERIALS AND METHODS**

**Participants**

Inpatients or outpatients treated at National Center Hospital, National Center of Neurology and Psychiatry, were enrolled. Participants were recruited by psychiatrists’ referrals. They provided written informed consent before starting the trial.

Subjects met the following inclusion criteria:

1. Meeting DSM-5 criteria for schizophrenia.
2. Being 20 through 60 years old.
3. Being able to sign and give consent.

Patients with any of the following diagnoses in accordance with clinical interview by psychiatrists were excluded from the study:

1. Alcohol or substance disorder
2. Traumatic brain injury
3. Epilepsy

Twenty-eight subjects were enrolled, and completed the study without any dropout. Baseline characteristics of patients are shown in Table 1. The mean and standard deviation of premorbid IQ assessed by the Japanese Adult Reading Test (25) was 99.6 (12.0). The mean standard deviation of the global assessment of functioning (26) was 38.6 (6.9). Antipsychotics taken by participants were as follows: risperidone (eight patients), paliperidone, quetiapine, aripiprazole (seven for each), olanzapine (six), haloperidol (three), chlorpromazine, levomepromazine, zotepine (two for each), perospirone, blonanserin, sulpiride (one for each). No medication was modified during the study period. No severe side effect was observed throughout the trial. All participants tolerated the treatment well.

**Intervention**

We used a Soterix Medical 1 × 1 Transcranial Direct Current Low-Intensity Stimulator Model 1,300 A. For each session, the tDCS montage comprised placement of the anode over the left DLPFC and the cathode over the right supraorbital area (corresponding to F3 and FP2, according to the International 10–20 electroencephalography system), as previously investigated (27). Rubber electrodes were inserted in 35-cm² saline-soaked sponges, and were fixed with headband. We applied direct current of 2 mA for 20 min per session. Subjects underwent 10 tDCS sessions in 5 consecutive days, twice per day. On each day, tDCS intervention was performed approximately at 10 a.m. and 2 p.m.

Trained psychiatrists administered tDCS intervention. In order to maximize adherence, we provided all included patients and

| Variables | Mean ± SD or n |
|-----------|---------------|
| Inpatient/outpatient | 22/6 |
| Male/female | 16/12 |
| Age, year | 40.9 ± 9.8 |
| Age at onset, year | 23.6 ± 6.7 |
| Duration of present illness, year | 17.3 ± 9.9 |
| Chlorpromazine equivalent dose of antipsychotics, mg/day | 889.0 ± 587.1 |
| Duration of education, year | 13.8 ± 1.7 |
| Premorbid IQ | 99.6 ± 12.0 |
| Global assessment of functioning | 38.6 ± 6.9 |
their study partners with costs of transportation, and reminded and rescheduled all of the patients’ visits if necessary.

Criteria for discontinuing interventions were as follows:

(1) In case patients withdraw informed consent to participate.
(2) In case severe adverse effects are observed.
(3) In case patients fail to undergo three consecutive sessions of tDCS.

Adjusting drugs were considered as a protocol deviation during the trial.

Outcome Measures
Subjects were assessed at baseline and 1 month after the last stimulation. Each evaluation was performed by experienced psychologists (Kazuki Sueyoshi and Crystal Lin). They were trained at a workshop.

Cognition
Cognitive function was assessed by the BACS. It is used to evaluate cognitive domains that are typically impaired in patients with schizophrenia, including verbal memory (Verbal Memory Task), verbal working memory (Digit Sequencing Task), motor/speed (Token Motor Task), verbal fluency (Verbal Fluency Task), attention/information processing (Symbol Coding Task), and executive function (Tower of London Task) (28). The higher scores represent better cognition. To provide a standard metric for combining test scores into domains and comparing performance over time, BACS scores were converted to $z$-scores (continuous variables) which show performances relative to those of healthy people (5). Alternative forms were used for the Verbal Memory Task and Tower of London Task at baseline and follow-up assessments.

Functional Capacity (Daily Living Skills)
Functional capacity was assessed by the UPSA-B (29). It is one of the measures most frequently used to evaluate daily living skills linked to cognitive function in schizophrenia (9, 29). Patients performed worse on the UPSA-B than do healthy individuals, a finding pertinent to some of the non-Western countries including Japan (9, 29). The UPSA-B consists of finance and communication subscales, which are continuous variables. Subscale scores of the two domains of the UPSA-B were converted into standard scores ranging from 0 to 50, so that the maximum of the total score was 100 (30). The higher scores represent better functional capacity. The validity of its Japanese version was confirmed (29).

Psychotic Symptoms
Psychotic symptoms were evaluated by the positive and negative syndrome scale (PANSS), commonly used for the assessment of psychotic symptoms of schizophrenia (31). The PANSS is a structured interview, consisting of positive, negative, and general psychopathology subscales (with scores ranging from 7 to 49, from 7 to 49, and from 16 to 112, respectively), whose scores are regarded as continuous variables. The higher scores represent more severe psychotic symptoms.

Depression
The Calgary depression scale for schizophrenia (CDSS), recommended as a brief and reliable tool for the assessment of severity of depression in schizophrenia (32), was used to assess depressive symptoms. The CDSS is a structured interview, consisting of items for depression, hopelessness, self-deprecation, guilty ideas of reference, pathological guilt, morning depression, early waking, suicide, and observed depression. The score of each item ranges from 0 to 3 (i.e., discrete variable) (32). The higher scores represent more severe depressive state.

This study was approved by Ethical Committee of National Center of Neurology and Psychiatry, Tokyo, Japan. This was a single-arm, open-label study in which outcome measures were carried out before and after tDCS intervention (UMIN000015953). The patients first underwent a baseline assessment of the BACS, UPSA-B, PANSS, and CDSS; then they participated in the stimulation protocol consisting in twice-daily (10 a.m. and 2 p.m.) anodal tDCS over the left DLPFC and cathodal tDCS on the right superorbital area for 5 days, and were assessed again 1 month after the last stimulation. The study schedule is summarized in Table 2.

Statistical Analysis
Correlations between baseline values and their changes from baseline of BACS, UPSA-B, PANSS, and CDSS scores, were evaluated. Correlations were also examined for chlorpromazine equivalent dose of antipsychotics vs. changes from baseline of BACS, UPSA-B, PANSS, and CDSS scores, as well as change from baseline of UPSA-B scores vs. changes from baseline of BACS, PANSS, and CDSS scores.

Statistical analysis was conducted using STATA 14, created by StataCorp in TX, USA. We performed a per protocol approach for subjects who were followed-up until the end of study point. For continuous variables in the BACS, UPSA-B, PANSS, we used Student’s $t$-test. For a discrete variable in the CDSS, we performed
Wilcoxon signed-rank test. Pearson's product moment correlation coefficient was used for the relationship between clinical variables.

**Monitoring**
A systematic review revealed that the most common adverse events were itching, tingling, headache, burning sensation, and discomfort (33). A trained psychiatrist evaluated the safety with a semistructured checklist of these symptoms after each intervention. An independent safety monitoring committee ran an interim analysis for safety every week.

**RESULTS**
Table 3 shows outcome measures at baseline and 1 month after the last administration of tDCS.

**Cognition**
Significant improvement was found on BACS composite scores ($t = 4.23, p < 0.001$), as well as on verbal memory ($t = 4.53, p < 0.001$), motor/speed ($t = 2.47, p = 0.020$), and verbal fluency ($t = 2.10, p = 0.046$) subtests. Improvement of verbal memory was associated with a largest effect size ($d = 0.55$), while small to medium effect sizes were noted for motor/speed ($d = 0.44$), verbal fluency ($d = 0.36$), and composite scores ($d = 0.49$). No significant improvement was found on working memory, attention/information processing, and executive function.

**Functional Capacity (Daily Living Skills)**
Significant improvement was noted on UPSA-B finance ($t = 3.35, p = 0.002$) and communication ($t = 3.57, p = 0.001$) subscale scores, as well as on total scores ($t = 5.89, p < 0.001$), with medium to large effect sizes ($d = 0.61, d = 0.59$, and $d = 0.70$, respectively).

**Psychotic Symptoms**
Significant improvement was found on PANSS positive ($t = 2.31, p = 0.029$) and general psychopathology ($t = 2.35, p = 0.027$) subscale scores, with medium effect sizes ($d = 0.48$ and $d = 0.58$, respectively). On the other hand, no significant improvement was found for negative syndrome subscale scores.

**Depression**
Significant improvement was demonstrated on self-depreciation ($z = 2.46, p = 0.014$), morning depression ($z = 2.12, p = 0.034$), early wakening ($z = 3.11, p = 0.002$), and suicide ($z = 1.99, p = 0.046$) item scores, as well as total scores ($z = 2.83, p = 0.005$) of the CDSS, with small to medium effect sizes ($r = 0.33, r = 0.28, r = 0.42, r = 0.27$, and $r = 0.38$, respectively). On the other hand, depression, hopelessness, guilty ideas of reference, pathological guilt, and observed depression items were not significantly changed.

### TABLE 3 | Outcome measures at baseline and 1 month after the treatment.

|                          | Baseline, mean ± SD | Follow-up, mean ± SD | $t$-Value (degree of freedom) or z-value | $p$-Value | Effect size |
|--------------------------|--------------------|----------------------|-----------------------------------------|-----------|-------------|
| **BACS (Z-SCORE)**      |                    |                      |                                          |           |             |
| Composite score          | $-1.88 ± 0.92$     | $-1.40 ± 0.93$       | $t = 4.23 (27)$                         | $<0.001$  | $d = 0.49$  |
| Verbal memory            | $-1.67 ± 1.06$     | $-1.06 ± 1.14$       | $t = 4.53 (27)$                         | $<0.001$  | $d = 0.55$  |
| Digit sequencing         | $-1.16 ± 1.38$     | $-0.95 ± 1.37$       | $t = 1.52 (27)$                         | $<0.001$  | $d = 0.15$  |
| Token motor              | $-2.15 ± 1.25$     | $-2.73 ± 1.23$       | $t = 2.47 (27)$                         | $0.020$   | $d = 0.44$  |
| Verbal fluency           | $-1.19 ± 1.06$     | $-0.84 ± 0.89$       | $t = 2.10 (27)$                         | $0.046$   | $d = 0.36$  |
| Symbol coding            | $-2.25 ± 1.22$     | $-2.21 ± 1.44$       | $t = 0.25 (27)$                         | $0.80$    | $d = 0.03$  |
| Tower of London          | $-1.76 ± 2.03$     | $-1.12 ± 2.16$       | $t = 1.88 (27)$                         | $0.071$   | $d = 0.31$  |
| **UPSA-B**               |                    |                      |                                          |           |             |
| Total                    | $68.4 ± 14.8$      | $79.0 ± 15.5$        | $t = 5.89 (27)$                         | $<0.001$  | $d = 0.70$  |
| Finance                  | $41.4 ± 8.1$       | $45.8 ± 6.2$         | $t = 3.35 (27)$                         | $0.002$   | $d = 0.61$  |
| Communication            | $27.1 ± 9.6$       | $33.2 ± 11.1$        | $t = 3.57 (27)$                         | $0.001$   | $d = 0.59$  |
| **PANSS**                |                    |                      |                                          |           |             |
| Positive syndrome        | $15.7 ± 5.7$       | $13.1 ± 4.8$         | $t = 2.31 (27)$                         | $0.029$   | $d = 0.48$  |
| Negative syndrome        | $14.9 ± 8.0$       | $13.6 ± 6.7$         | $t = 1.24 (27)$                         | $0.23$    | $d = 0.17$  |
| General psychopathology  | $32 ± 8.1$         | $28.3 ± 7.1$         | $t = 2.35 (27)$                         | $0.027$   | $d = 0.50$  |
| **CDSS**                 |                    |                      |                                          |           |             |
| Total                    | $8.00 ± 4.97$      | $5.36 ± 3.89$        | $z = 2.83$                              | $0.005$   | $r = 0.38$  |
| Depression               | $0.79 ± 0.79$      | $0.89 ± 0.92$        | $z = 0.79$                              | $0.43$    | $r = -0.11$ |
| Hopelessness             | $0.86 ± 0.93$      | $0.57 ± 0.74$        | $z = 1.58$                              | $0.11$    | $r = 0.21$  |
| Self-depreciation        | $1.21 ± 1.17$      | $0.71 ± 0.85$        | $z = 2.46$                              | $0.014$   | $r = 0.33$  |
| Guilty ideas of reference| $0.75 ± 1.04$      | $0.50 ± 0.64$        | $z = 0.39$                              | $0.39$    | $r = 0.11$  |
| Pathological guilt       | $0.82 ± 0.90$      | $0.57 ± 0.88$        | $z = 1.58$                              | $0.11$    | $r = 0.21$  |
| Morning depression       | $0.82 ± 0.72$      | $0.61 ± 0.63$        | $z = 2.12$                              | $0.034$   | $r = 0.28$  |
| Early wakening           | $1.68 ± 1.25$      | $1.00 ± 0.86$        | $z = 3.11$                              | $0.002$   | $r = 0.42$  |
| Suicide                  | $0.61 ± 0.83$      | $0.25 ± 0.52$        | $z = 1.99$                              | $0.046$   | $r = 0.27$  |
| Observed depression      | $0.48 ± 0.51$      | $0.25 ± 0.44$        | $z = 1.90$                              | $0.058$   | $r = 0.25$  |

BACS, The Brief Assessment for Cognition in Schizophrenia; UPSA-B, The UCSD Performance-based Skills Assessment-Brief; PANSS, Positive and Negative Syndrome Scale; CDSS, Calgary Depression Scale for Schizophrenia.
Correlation

No significant correlation was noted between baseline values and their changes from baseline of BACS and UPSA-B scores. In contrast, significant negative correlations were demonstrated between baseline values vs. their changes from baseline of PANSS positive subscales ($r = -0.65, p < 0.001$, Figure 1), negative subscales ($r = -0.56, p < 0.002$, Figure 2), general psychopathology subscales ($r = -0.64, p < 0.001$, Figure 3), and CDSS total scores ($r = -0.66, p < 0.001$, Figure 4). No significant correlation was found between chlorpromazine equivalent dose of antipsychotics vs. changes from baseline of BACS, UPSA-B, PANSS, and CDSS scores. The same applied to correlations between change from baseline of UPSA-B scores vs. changes from baseline of BACS, PANSS, and CDSS scores.

DISCUSSION

To our knowledge, this study was the first to suggest the ability of tDCS to improve daily living skills linked to cognition (functional capacity, measured by UPSA-B), as well as depressive symptoms (measured by the CDSS) in patients with schizophrenia. Also, this study was the first to indicate the improvement of functional capacity after 5-day administration of tDCS, which was not correlated with the change of cognition, psychosis, and depression. At the same time, tDCS was found to enhance cognition in these subjects.

The results obtained in this trial are consistent with those from other studies indicating that tDCS may be effective to improve cognition in healthy controls (34–36) and patients with schizophrenia (18, 22, 23, 37). In a previous study, five sessions of tDCS in consecutive days, with the anode over F3 and the cathode over FP2, enhanced working memory and attention/vigilance to a greater extent than did sham-treatment in patients with schizophrenia (24). In our study, significant effects of tDCS were noted in the domains of verbal memory capacity.
connectivity of the frontoparietal control network and inter-assessments with the same tests could produce learning effects. This discrepancy may be due to the difference in the study design, treatment regimen (5 session of tDCS in consecutive days in the previous study, while 10 sessions of tDCS in 5 consecutive days in our study), and/or sample size. It is also possible that an effect on working memory might have vanished in 1-month follow-up period. In this sense, the inclusion of data on the cognitive outcomes immediately after the last stimulation could have provided more detailed information. While a previous study evaluated working memory immediately after the last tDCS (24, 38), the measurement of the BACS and UPSA-B at this time-point were not included in our protocol. This was because evaluating the BACS and UPSA-B just 1 week after baseline assessments with the same tests could produce learning effects.

The mechanisms by which tDCS affects cognitive function in schizophrenia may be explained in several ways. Functional connectivity of the frontoparietal control network and inter-hemispheric connectivity are decreased in schizophrenia patients, likely to be related to impairment of higher order cognitive task-related activities and disruption of the default mode network (10–12). Several studies demonstrated that tDCS alters functional connectivity in, for example, the default mode network and the frontoparietal control network, in healthy subjects (39, 40). Also, a case study reported that tDCS changed functional brain connectivity in the anterior part of the default mode network (41). Furthermore, Kim et al. reported neurophysiological evidence that tDCS modulates sensory gating in schizophrenia (42). Neurochemically, the after-effects of anodal tDCS are considered to depend on modulation of both GABAergic and glutamatergic synaptic transmissions (17). Further investigations of biological measures are warranted to elucidate the mechanisms by which tDCS exerts pro-cognitive effects.

tDCS was also found to improve daily living skills linked to cognition (functional capacity), measured by the UPSA-B with medium to large effect sizes, in schizophrenia. To our knowledge, there has been no attempt to elucidate the effect of tDCS on this level of functional outcomes in psychiatric conditions. In view of the association between performance on the UPSA-B and real-world functional outcomes (43), the result reported here suggests the ability of tDCS to enhance social outcome in schizophrenia.

Data from this study also suggest the ability of tDCS to ameliorate depressive mood, evaluated objectively by the CDSS (32), in patients with schizophrenia. Results from a meta-analysis indicate that tDCS is effective in treating patients with major depressive disorder, with an effect size comparable with those reported for repetitive transcranial magnetic stimulation and antidepressant drugs (44). Some domains in depressive symptoms were improved with small to medium effect sizes, similar to the case in patients with major depressive disorder (44). The antidepressant effect of tDCS may be related to hypoactivity of the left DLPFC, which is likely to be restored by anodal tDCS (45). The results presented in the current study are consistent with this hypothesis, and may provide a strategy to ameliorate treatment-resistant depressive symptoms in patients with schizophrenia.

tDCS was found to improve positive symptoms and general psychopathology with medium effect sizes, which is advantageous for patients suffering from psychotic symptoms. So far, two studies have attempted to see the effect of tDCS on psychopathology, as measured by the PANSS. Brunelin et al. did not find a significant effect on either positive or negative symptoms. These authors placed the anodal electrode over a point midway between F3 and FP1 and the cathodal electrode over a point midway between T3 and P3 (46). On the other hand, Smith et al. observed significant improvement only in negative symptoms. These investigators placed the anode over F3 and the cathode over FP2 (24). Taken together, further studies to seek optimal methods of tDCS to ameliorate psychotic symptoms are needed.

Changes of cognition and daily living skills were not correlated with their baseline scores. In contrast, the improvements of positive symptoms, negative symptoms, general psychopathology, and depression were correlated with their baseline scores. These observations suggest the lack of ceiling effects of tDCS on cognition and daily living skills. Also, the lack of significant correlation between chlorpromazine equivalent dose of antipsychotics vs. the improvement of cognition, functional outcome, psychotic symptoms, and depression suggests that tDCS may improve these outcome measures regardless of the dose of antipsychotics. Furthermore, the lack of significant correlation between the improvement of functional capacity vs. cognition, positive symptoms, and depression, indicates that the observed change of functional capacity was independent of these clinical variables. However, the possibility of unobserved confounders cannot be ruled out completely with the current study design.

The limitations of this study should be noted here. The lack of blinding might have produced practice (repeated-measure) effect in some measures used. To circumvent this issue, alternate forms were used for verbal memory (word list learning task) and executive function (Tower of London task) in the BACS at the follow-up assessment. Therefore, the pro-cognitive effect of tDCS on verbal memory may not be attributable to repeated-measure effect. In addition, a small sample of this study may raise caution in concluding that these results represent effects in the population. Also, the lack of randomization, controlled group, and blinding might have produced placebo effects. Inclusion of a sham-controlled group could have provided a definitive conclusion. Accordingly, we are initiating a randomized sham-controlled trial with a larger sample (Narita, et al. submitted; UMIN000028224).

In conclusion, the results of the present study suggest the efficacy of tDCS on cognition, daily living skills, and depression. These results may add to the concept that tDCS provides a strategy to enhance functional outcomes in patients with schizophrenia.

ETHICS STATEMENT

This study was carried out in accordance with the recommendations of Ethical Guideline for Clinical Researches, Ministry of
Health, Labor and Welfare with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Ethical Committee of National Center of Neurology and Psychiatry.

AUTHOR CONTRIBUTIONS

ZN managed the literature searches, undertook the statistical analysis, and wrote the first draft of the manuscript. TI, TS, and ZN administered tDCS. TS designed the study and wrote the protocol. CL and KS conducted clinical assessments. All authors made substantial contribution, drafted the manuscript, and approved the final manuscript.

REFERENCES

1. Kremen WS, Vinogradov S, Poole JH, Schafer CA, Deicken RF, Factor-Litvak P, et al. Cognitive decline in schizophrenia from childhood to midlife: a 33-year longitudinal birth cohort study. Schizophr Res (2010) 118(1–3):1–5. doi:10.1016/j.schres.2010.01.009
2. Kurtz MM. Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophr Res (2005) 74(1):15–26. doi:10.1016/j.schres.2004.07.005
3. Micaleff J, Fakra E, Blin O. [Use of antidepressant drugs in schizophrenic disorders, National Center of Neurology and Psychiatry.]
4. Green MF, Nuechterlein KH, Kern RS, Baade LE, Fenton WS, Gold JM, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry (1994) 51(2):124–31. doi:10.1001/ archpsyc.1994.018010300030007
5. Saykin AJ, Gur RC, Gur RE, Mozley LH, Resnick SM, et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry (1991) 48(7):618–24. doi:10.1001/archpsyc.1991.018010310030007
6. Green MF, Nuechterlein KH, Kern RS, Raade LE, Fenton WS, Gold JM, et al. Functional co-primacy measures for clinical trials in schizophrenia: results from the MATRICS psychometric and standardization study. Am J Psychiatry (2008) 165(2):221–8. doi:10.1176/appi.ajp.2007.07070089
7. Harvey PD, Velligan DI. International assessment of functional skills in people with schizophrenia. Innov Clin Neurosci (2011) 8(1):1–15.
8. Harvey PD, Raykov T, Twamley EW, Vella L, Heaton RK, Patterson TL. Validating the measurement of real-world functional outcomes: phase I results of the VALERO study. Am J Psychiatry (2011) 168(11):1195–201. doi:10.1176/appi.ajp.2011.1211273
9. Sumiyoshi T, Nishida K, Niimura H, Toyomaki A, Morimoto T, Tani M, et al. Cognitive and functional outcome in schizophrenia: a multi-center collaborative study with the specific level of functioning scale – Japanese version. Schizophr Res Cogn (2016) 6:9–14. doi:10.1016/j.scog.2016.08.001
10. Baker JT, Holmes AJ, Masters GA, Yeo BTT, Krienzen F, Buckner RL, et al. Disruption of cortical association networks in schizophrenia and psychotic bipolar disorder. JAMA Psychiatry (2014) 71(2):109–18. doi:10.1001/jamapsychiatry.2013.3469
11. Guo W, Xiao C, Liu G, Wooderson SC, Zhang Z, Zhang J, et al. Decreased resting-state interhemispheric coordination in first-episode, drug-naïve paranoid schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2014) 48:14–9. doi:10.1016/j.pnpbp.2013.09.012
12. Hoptman MJ, Zuo X-N, D’Angelo D, Mauro CJ, Butler PD, Milham MP, et al. Decreased interhemispheric coordination in schizophrenia: a resting state fMRI study. Schizophr Res (2012) 141(1):1–7. doi:10.1016/j.schres.2012.07.027
13. Sheffield JM, Repovs G, Harms MP, Carter CS, Gold JM, MacDonald AW, et al. Fronto-parietal and cingulo-opercular network integrity and cognition in health and schizophrenia. Neuropsychologia (2015) 73:82–93. doi:10.1016/j.neuropsychologia.2015.05.006
14. Sheffield JM, Barch DM. Cognition and resting-state functional connectivity in schizophrenia. Neurosci Biobehav Rev (2016) 61:108–20. doi:10.1016/j.neubiorev.2015.12.007
15. Yokoi Y, Narita Z, Sumiyoshi T. Transcranial direct current stimulation in depression and psychosis: a systematic review. Clin EEG Neurosci (2017) (in press).
16. Yokoi Y, Sumiyoshi T. Application of transcranial direct current stimulation to psychiatric disorders: trends and perspectives. Neuropsychiatr Electrophysiol (2015) 1:10. doi:10.1186/s40810-015-0012-x
17. Stagg CJ, Nitsche MA. Physiological basis of transcranial direct current stimulation. Neuroscientist (2011) 17(1):37–53. doi:10.1177/1073858610386614
18. Schreiten DL, van Steenburgh JJ, Varvaris M, Vannorsdall TD, Andrejczuk MA, Gordon B. Can transcranial direct current stimulation improve cognitive functioning in adults with schizophrenia? Clin Schizophr Relat Psychoses (2014) 3:1–27. doi:10.3371/CSRP.SCST.103114
19. Sumiyoshi T, Higuchi Y. Facilitative effect of serotonin(1A) receptor agonists in patients with schizophrenia. Curr Med Chem (2013) 20(3):357–62. doi:10.2174/092986713804870846
20. Stagg CJ, Lin RL, Mezeu M, Segerdahl A, Kong Y, Xie J, et al. Widespread modulation of cerebral perfusion induced during and after transcranial direct current stimulation applied to the left dorsolateral prefrontal cortex. J Neurosci (2013) 33(28):11425–31. doi:10.1523/JNEUROSCI.3887-12.2013
21. Lorenz J, Minoshima S, Casey KL. Keeping pain out of mind: the role of the dorsolateral prefrontal cortex in pain modulation. Brain (2003) 126(Pt 5):1079–91. doi:10.1093/brain/awg102
22. Vercammen A, Rushby JA, Loo C, Short B, Weikert CS, Weikert TW. Transcranial direct current stimulation influences probabilistic association learning in schizophrenia. Schizophr Res (2011) 131(1–3):198–205. doi:10.1016/j.schres.2011.06.021
23. Hoy KE, Bailey NW, Arnold SL, Fitzgerald PB. The effect of transcranial direct current stimulation on gamma activity and working memory in schizophrenia. Psychiatry Res (2015) 228(2):191–6. doi:10.1016/j.psychres.2015.04.032
24. Smith RC, Boules S, Mattiau S, Youssef M, Tobe RH, Sershen H, et al. Effects of transcranial direct current stimulation (tDCS) on cognition, symptoms, and smoking in schizophrenia: a randomized controlled study. Schizophr Res (2015) 168(1–2):260–6. doi:10.1016/j.schres.2015.06.011
25. Fukue T, Fukue M, Ishizuka Y. Relationship between Japanese adult reading test (JART) and cognitive dysfunction. Jpn J Gen Hosp Psychiatry (2013) 25(1):55–62.
26. Hall RC. Global assessment of functioning. A modified scale. Psychosomatics (1995) 36(3):276–75. doi:10.1016/s0033-3182(95)71666-8
27. Boggio PS, Rigonatti SP, Ribeiro RB, Myczkowski ML, Nitsche MA, Pascual-Leone A, et al. A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression. Int J Neuropsychopharmacol (2008) 11(2):249–54. doi:10.1017/s1461145707007833
28. Segarra N, Bernardo M, Gutierrez F, Justicia A, Fernadez-Egea E, Allas M, et al. Spanish validation of the brief assessment in cognition in schizophrenia (BACS) in patients with schizophrenia and healthy controls. Eur Psychiatry (2011) 26(2):69–73. doi:10.1016/j.eurpsy.2009.11.001

ACKNOWLEDGMENTS

The authors thank Dr. Yuma Yokoi, Dr. Satoru Ikezawa, Dr. Harumasa Takano, Dr. Mitsutoshi Okazaki, Dr. En Kimura, and Dr. Kazuyuki Nakagome for fruitful discussions, Dr. Haruka Matsuda, Dr. Naonori Yasuma, Dr. Aiihiro Nakajima, Dr. Takaaki Nakayama, Dr. Yusuke Toguchi, and Dr. Naoki Yoshimura for recruitment of participants.

FUNDING

This study was funded by Kakenhi (kiban-C) No.26461761 and 17K10321, Japan Society for the Promotion of Science. Intramural Research Grant (27-1, 29-1, 27-6-2) for Neurological and Psychiatric Disorders, National Center of Neurology and Psychiatry.
31. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. *Psychiatry Res* (1988) 23(1):99–110. doi:10.1016/0165-1781(88)90038-8

32. Bernard D, Lanoë C, Auquier P, Reine G, Addington D. Calgary depression scale for schizophrenia: a study of the validity of a French-language version in a population of schizophrenic patients. *Acta Psychiatr Scand* (1998) 97(1):36–41. doi:10.1111/j.1600-0447.1998.tb09960.x

33. Brunoni AR, Amadiera J, Berbel B, Volz MS, Rizzerio BG, Fregni F. A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. *Int J Neuropsychopharmacol* (2011) 14(8):1133–45. doi:10.1017/S1461145710001690

34. Brasil-Neto JP. Learning, memory, and transcranial direct current stimulation. *Front Psychiatry* (2012) 3:80. doi:10.3389/fpsyt.2012.00080

35. Jeon SY, Han SJ. Improvement of the working memory and naming by transcranial direct current stimulation. *Ann Rehabil Med* (2012) 36(5):585–95. doi:10.5355/arm.2012.36.5.585

36. Nelson JT, McKinley RA, Golob EJ, Warm JS, Parasuraman R. Enhancing vigilance in operators with prefrontal cortex transcranial direct current stimulation (tDCS). *NeuroImage* (2014) 85(Pt 3):909–17. doi:10.1016/j.neuroimage.2012.11.061

37. Tarur Padinjareveetil AM, Rogers J, Loo C, Martin D. Transcranial direct current stimulation to enhance cognitive remediation in schizophrenia. *Brain Stimulat* (2015) 8(2):307–9. doi:10.1016/j.brs.2014.11.012

38. Frohlich F, Burrello TN, Mellin JM, Cordle AL, Lustenberger CM, Gilmore JH, et al. Exploratory study of once-daily transcranial direct current stimulation (tDCS) as a treatment for auditory hallucinations in schizophrenia. *Eur Psychiatry* (2016) 33:54–60. doi:10.1016/j.eurpsy.2015.11.005

39. Keeser D, Meindl T, Bor J, Palm U, Pogarell O, Mulert C, et al. Prefrontal transcranial direct current stimulation changes connectivity of resting-state networks during fMRI. *J Neurosci* (2011) 31(43):15284–93. doi:10.1523/JNEUROSCI.0542-11.2011

40. Peña-Gómez C, Sala-Lonch R, Junqué C, Clemente IC, Vidal D, Bargalló N, et al. Modulation of large-scale brain networks by transcranial direct current stimulation evidenced by resting-state functional MRI. *Brain Stimulat* (2012) 5(3):252–63. doi:10.1016/j.brs.2011.08.006

41. Palm U, Keeser D, Blautzik J, Pogarell O, Ertl-Wagner B, Kupka M, et al. Prefrontal transcranial direct current stimulation (tDCS) changes negative symptoms and functional connectivity MRI (fMRI) in a single case of treatment-resistant schizophrenia. *Schizophr Res* (2013) 150(2–3):583–5. doi:10.1016/j.schres.2013.08.043

42. Kim M, Yoon YB, Lee TH, Lee TY, Kwon JS. The effect of tDCS on auditory hallucination and P50 sensory gating in patients with schizophrenia: a pilot study. *Schizophr Res* (2017). doi:10.1016/j.schres.2017.04.023

43. Sumiyoshi C, Harvey PD, Takaki M, Okahisa Y, Sato T, Sora I, et al. Factors predicting work outcome in Japanese patients with schizophrenia: role of multiple functioning levels. *Schizophr Res Cogn* (2015) 2(3):105–12. doi:10.1016/j.scog.2015.07.003

44. Brunoni AR, Moffa AH, Fregni F, Palm U, Padberg F, Blumberger DM, et al. Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data. *Br J Psychiatry* (2016) 208(6):522–31. doi:10.1192/bjp.bp.115.164715

45. Brunoni AR, Teng CT, Correa C, Imamura M, Brasil-Neto JP, Boechat R, et al. Neuromodulation approaches for the treatment of major depression: challenges and recommendations from a working group meeting. *Anq Neuropsiquiatr* (2010) 68(3):433–51. doi:10.1590/S0004-282X2010000300021

46. Brunelin J, Mondino M, Gassab L, Haesebaert F, Gaha L, Suad-Chagny M-E, et al. Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. *Am J Psychiatry* (2012) 169(7):719–24. doi:10.1176/appi.ajp.2011.11071091

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

---

*Copyright © 2017 Narita, Inagawa, Sueyoshi, Lin and Sumiyoshi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*